GlobeNewswire: Given Imaging Ltd. Contains the last 10 of 32 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T04:50:40ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2014/02/03/606574/10066581/en/Multimedia-Release-Given-Imaging-Receives-FDA-Clearance-for-PillCam-R-COLON-in-Patients-Following-Incomplete-Colonoscopy.html?f=22&fvtc=4&fvtv=19069Multimedia Release -- Given Imaging Receives FDA Clearance for PillCam(R) COLON in Patients Following Incomplete Colonoscopy2014-02-03T06:00:00Z<![CDATA[PillCam COLON is the Only Non-Invasive and Radiation-Free Solution for the Approximately 750,000 Patients in the U.S. Who Experience an Incomplete Colonoscopy Each Year]]>PillCam COLONhttps://www.globenewswire.com/news-release/2014/02/03/606574/10066581/en/Multimedia-Release-Given-Imaging-Receives-FDA-Clearance-for-PillCam-R-COLON-in-Patients-Following-Incomplete-Colonoscopy.htmlPillCam COLON 2https://www.globenewswire.com/news-release/2014/02/03/606574/10066581/en/Multimedia-Release-Given-Imaging-Receives-FDA-Clearance-for-PillCam-R-COLON-in-Patients-Following-Incomplete-Colonoscopy.htmlPillCam COLON Animationhttps://www.globenewswire.com/news-release/2014/01/23/604344/10065249/en/Given-Imaging-Announces-Results-of-Special-Shareholders-Meeting.html?f=22&fvtc=4&fvtv=19069Given Imaging Announces Results of Special Shareholders' Meeting2014-01-23T15:37:52Z<![CDATA[YOQNEAM, Israel, Jan. 23, 2014 (GLOBE NEWSWIRE) -- Given Imaging Ltd. (Nasdaq:GIVN) announced that at a special shareholders' meeting held today in Yoqneam, Israel, the shareholders of the Company approved the Merger Proposal described in the Proxy Statement dated December 24, 2013, including the merger between the Company and a subsidiary of Covidien Group S.a.r.l., a Luxembourg company and an indirect, wholly-owned subsidiary of Covidien plc, as a result of which the Company will become a wholly-owned subsidiary of Covidien.]]>https://www.globenewswire.com/news-release/2014/01/02/599880/10062690/en/Given-Imaging-Announces-Results-of-Special-Shareholders-Meeting.html?f=22&fvtc=4&fvtv=19069Given Imaging Announces Results of Special Shareholders' Meeting2014-01-02T12:00:00Z<![CDATA[YOQNEAM, Israel, Jan. 2, 2014 (GLOBE NEWSWIRE) -- Given Imaging Ltd. (Nasdaq:GIVN) today announced the results of a special shareholders' meeting which was held in Yoqneam, Israel on December 31, 2013. A total of 22,438,880 shares, or approximately 69.8%, of the total number of shares entitled to vote at the meeting were represented. All proposals were approved, except for Proposal 3 concerning equity grants to our external directors, which failed to achieve support from a majority of non-controlling shareholders, as required by Israeli law.]]>https://www.globenewswire.com/news-release/2013/11/11/588474/10057254/en/Photo-Release-Given-Imaging-Receives-Reimbursement-Approval-for-PillCam-COLON-R-in-Japan-Effective-January-1-2014.html?f=22&fvtc=4&fvtv=19069Photo Release -- Given Imaging Receives Reimbursement Approval for PillCam COLON(R) in Japan Effective January 1, 20142013-11-11T06:00:00Z<![CDATA[YOQNEAM, Israel, Nov. 11, 2013 (GLOBE NEWSWIRE) -- Given Imaging (Nasdaq:GIVN), a world leader in specialty GI products and pioneer of capsule endoscopy, today announced that Japan's Central Social Insurance Medical Council (Chuikyo) has approved the recommendation by the Japanese Ministry of Health, Labor and Welfare (MHLW) to provide reimbursement for Given Imaging's PillCam COLON. With this approval, Chuikyo established a reimbursement of 83,100 JPY, or roughly $840.00 USD (using current exchange rate), per capsule that is scheduled to go into effect on January 1, 2014. This decision follows regulatory clearance of PillCam COLON in July of this year by Japan's Pharmaceuticals & Medical Devices Agency (PMDA). The MHLW will determine the final indication for use for PillCam COLON in December as well as the amount for the professional fee.]]>PillCam COLON
PillCam COLONhttps://www.globenewswire.com/news-release/2013/11/05/586999/10056382/en/Given-Imaging-Reports-Third-Quarter-2013-Financial-Results.html?f=22&fvtc=4&fvtv=19069Given Imaging Reports Third Quarter 2013 Financial Results2013-11-05T21:47:19Z<![CDATA[
Third Quarter 2013 Revenues Increase by 10% to a Record $50 Million]]>https://www.globenewswire.com/news-release/2013/10/22/582203/10053607/en/Given-Imaging-to-Host-Third-Quarter-2013-Financial-Results-Conference-Call-on-November-6-2013.html?f=22&fvtc=4&fvtv=19069Given Imaging to Host Third Quarter 2013 Financial Results Conference Call on November 6, 20132013-10-22T11:00:00Z<![CDATA[YOQNEAM, Israel, Oct. 22, 2013 (GLOBE NEWSWIRE) -- Given Imaging (Nasdaq:GIVN) today announced that the company will host a conference call on Wednesday, November 6, 2013 at 9:00am ET, 4:00pm Israel time to discuss third quarter 2013 financial results. The company plans to release results following the close of U.S. financial markets on Tuesday, November 5, 2013.]]>https://www.globenewswire.com/news-release/2013/10/21/581965/10053484/en/Given-Imaging-Announces-the-Results-of-Two-Recent-Studies-Underscoring-the-Economic-Value-and-Clinical-Utility-of-PillCam-R-ESO-in-Managing-Upper-GI-Bleeding-in-the-Emergency-Depar.html?f=22&fvtc=4&fvtv=19069Given Imaging Announces the Results of Two Recent Studies Underscoring the Economic Value and Clinical Utility of PillCam(R) ESO in Managing Upper GI Bleeding in the Emergency Department Setting2013-10-21T16:30:00Z<![CDATA[- Cost analysis shows PillCam ESO saves more than $10,000 versus a scoring-based risk stratification strategy for patients at low risk -]]>https://www.globenewswire.com/news-release/2013/10/16/580819/10052757/en/Studies-Presented-at-ACG-Confirm-the-Use-of-Given-Imaging-s-High-Resolution-Manometry-and-Reflux-Products-to-Measure-Esophageal-Dysfunction-and-Symptom-Severity-Leading-to-Altered-.html?f=22&fvtc=4&fvtv=19069Studies Presented at ACG Confirm the Use of Given Imaging's High Resolution Manometry and Reflux Products to Measure Esophageal Dysfunction and Symptom Severity Leading to Altered Disease Management2013-10-16T11:01:00Z<![CDATA[SAN DIEGO, Oct. 16, 2013 (GLOBE NEWSWIRE) -- Given Imaging (Nasdaq:GIVN), a world leader in GI medical devices and pioneer of capsule endoscopy, today announced results from multiple studies that showed the positive impact of ManoScan]]>https://www.globenewswire.com/news-release/2013/10/16/580701/10052751/en/New-Data-Confirm-Given-Imaging-s-Reflux-and-Manometry-Monitoring-Products-Improve-Detection-Management-of-GERD-and-Other-Esophageal-Disorders.html?f=22&fvtc=4&fvtv=19069New Data Confirm Given Imaging's Reflux and Manometry Monitoring Products Improve Detection & Management of GERD and Other Esophageal Disorders2013-10-16T05:01:00Z<![CDATA[BERLIN, Oct. 16, 2013 (GLOBE NEWSWIRE) -- Given Imaging (Nasdaq:GIVN), a world leader in specialty GI products and pioneer of capsule endoscopy, today announced numerous studies confirming the value of its reflux and manometry products in diagnosing, monitoring and managing a range of gastrointestinal diseases. The studies were presented at United European Gastroenterology Week (UEG Week), taking place from October 12-16, 2013 at the Internationales Congress Centrum Berlin where Given Imaging is exhibiting at Hall 15.1, Booth #7 throughout the conference. Results of more than 110 clinical studies of Given Imaging's products were presented at UEG Week this year demonstrating the breadth and utility of its portfolio.]]>https://www.globenewswire.com/news-release/2013/10/15/580472/10052545/en/Given-Imaging-Announces-Data-Confirming-PillCam-R-SB-Can-Improve-Management-and-Outcomes-in-Patients-With-Crohn-s-Disease.html?f=22&fvtc=4&fvtv=19069Given Imaging Announces Data Confirming PillCam(R) SB Can Improve Management and Outcomes in Patients With Crohn's Disease2013-10-15T11:01:00Z<![CDATA[Additional Survey Reveals a Majority of Gastroenterologists Recommend Monitoring Patients Even After Mucosal Healing is Achieved SAN DIEGO, Oct. 15, 2013 (GLOBE NEWSWIRE) -- Given Imaging (Nasdaq:GIVN), a world leader in specialty GI products and pioneer of capsule endoscopy, today announced new studies validating PillCam SB's role in improving care, management and outcomes for patients with known or suspected Crohn's disease. The studies were presented at the American College of Gastroenterology's Annual Scientific Meeting and Postgraduate Course (ACG), taking place October 11-16, 2013, at the San Diego Convention Center, San Diego, CA, where Given Imaging is exhibiting at booth #1200 throughout the conference.]]>